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Purpose: GPR109A has been identified as a G-protein-coupled receptor for niacin. β-hydroxybutyrate (β-HB) is a
physiologic ligand for the receptor. β-HB, the predominate ketone body in circulation, is an important energy source for
neurons, including retinal neurons, under various physiologic and pathologic conditions. The identification of GPR109A
as the receptor for β-HB suggests additional, hitherto unknown, functions for this metabolite. The circulating levels of
β-HB increase in diabetes. Since retinopathy is a serious complication associated with diabetes, we investigated GPR109A
expression in retina and in different retinal cell types to determine if the receptor may have a role in the pathophysiology
of diabetic retinopathy.
Methods: RT–PCR, fluorescent in situ hybridization, and immunofluorescent techniques were used to analyze GPR109A
expression in mouse retina and in three transformed retinal cell lines: ARPE-19 (RPE), RGC-5 (ganglion), and rMC-1
(Müller). Activation of GPR109A by niacin and β-HB was demonstrated in ARPE-19 cells by cAMP assay.
Results: Studies conducted using mouse retinal tissues demonstrated that GPR109A is expressed in retina with its
expression restricted to RPE, where it differentially polarizes to the basolateral membrane. These results were confirmed
with cell lines, which demonstrated GPR109A expression in ARPE-19, but not in rMC-1 and RGC-5 cells. Primary cultures
of mouse RPE also showed robust expression of GPR109A. cAMP assay demonstrated that GPR109A expressed in RPE
is functional.
Conclusions: These data represent the first report on GPR109A expression in retina. The exclusive expression of
GPR109A in RPE basolateral membrane, which has access to β-HB in blood, may have biologic importance in diabetic
retinopathy.
G protein-coupled receptors (GPCRs) comprise a large
protein family of transmembrane receptors that play pivotal
roles  in  several  biologic  processes.  As  such,  GPCRs  are
currently  the  target  of  several  pharmaceuticals  aimed  at
treating pain, inflammation, and a broad range of diseases
including cancer, cardiac disease, and diabetes [1,2]. Of the
more  than  700  GPCRs  identified  by  the  Human  Genome
Project,  150  or  more  of  these  receptors  are  annotated  as
“orphan”  or  functionally  uncharacterized  [3].  Prior  to  its
identification as the nicotinic acid (niacin) receptor [4-6],
GPR109A was classified also as an orphan GPCR. GPR109A
is  expressed  primarily  in  adipocytes  and  immune  cells.
Indeed,  it  is  the  abundant  expression  of  the  receptor  in
adipocytes that led to its identification as the receptor for
niacin, a drug widely used for decades in the treatment of
hyperlipidemia.  GPR109A  is  coupled  to  the  inhibitory  G
protein Gi. Activation of the receptor with its ligands results
in a pertussis toxin-sensitive decrease in cAMP levels. One of
the actions of cAMP in adipocytes is to stimulate the hormone-
sensitive lipase by protein phosphorylation, which leads to
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triglyceride hydrolysis and release of free fatty acids into the
circulation.  Niacin,  by  its  ability  to  reduce  cAMP  levels,
decreases the activity of lipase and prevents the release of free
fatty acids from fat stores.
While the discovery of GPR109A as a receptor for niacin
helps to explain the mechanism of action of the drug, it sheds
little light on any physiologic function of the receptor, as
circulating levels of niacin in normal individuals not taking
the drug for therapeutic purposes are too low to activate the
receptor  [5,7].  This  led  to  the  identification  of  β-
hydroxybutyrate  (β-HB)  as  the  physiologic  ligand  for  the
receptor [8]. As with niacin, interaction of β-HB with the
receptor decreases intracellular cAMP levels. Since β-HB is
generated in the liver from fatty acid oxidation following fat
mobilization  from  adipocytes,  it  is  believed  that  β-HB,
through its interaction with GPR109A present on adipocytes,
may inhibit triglyceride hydrolysis and release of free fatty
acids  as  a  negative  feedback  regulatory  mechanism,
promoting the maintenance of metabolic homeostasis during
conditions such as starvation and diabetes [8].
Though  GPR109A  is  most  noted  for  its anti-lipolytic
effects  in  adipocytes,  recent  studies  demonstrate  that  the
activation  of  the  receptor  produces  differential  responses
depending on the location/cell-type in which the receptor is
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362expressed. For example, activation of GPR109A on dermal
dendritic  cells  or  dermal  macrophages  mediates  the
characteristic cutaneous vasodilation or “flushing” response
associated with chronic therapeutic use of niacin, an effect
very different from the antilipolytic actions seen in adipocytes
[9].  In  murine  macrophages,  GPR109A  expression  is
upregulated by cytokines such as interferon-gamma (IFN-γ)
[10],  suggesting  a  role  for  GPR109A  in  immunity  and
inflammation. Thus, GPR109A expression and function likely
extends beyond adipocytes and immune cells.
In  the  present  study,  we  asked  whether  GPR109A  is
expressed also in retina. We were interested in expression of
the receptor in this tissue for several reasons. First, chronic
use of niacin at high doses necessary for therapeutic efficacy
as  a  lipid-lowering  agent  is  associated  with  several  side
effects, including an ocular complication known as niacin
maculopathy [11-13]. This suggests that the niacin receptor
GPR109A may be present also in retina and contribute to the
pathogenesis  of  maculopathy.  Second,  activation  of
GPR109A is associated with decreased cAMP levels. The
essential role of cAMP in maintenance of neuronal health in
retina  and  overall  visual  function  is  widely  accepted,  as
alterations  in  cAMP  levels  severely  compromise  retinal
function [14-17]. Thus, if GPR109A is expressed in retina, it
is possible that alterations in cAMP levels as a consequence
of GPR109A activation might play a role in these vital retinal
processes.  Under  normal  physiologic  conditions,  in  the
absence of niacin drug therapy, this would likely be of little
relevance; β-HB, the predominant ketone body in circulation
and endogenous ligand for GPR109A, is normally found at
low  levels  in  the  circulation  (<50  μM),  concentrations
insufficient to activate the receptor (concentrations necessary
to elicit half-maximal effect on the receptor, 300–800 μM).
β-HB  levels  increase  several-fold  (approximately  3  mM),
however, during periods of prolonged fasting, starvation, and
strenuous  exercise  to  maintain  the  energy  status  in  vital
organs, including brain and retina. The same is true in poorly
controlled  diabetes  (especially  type  1  diabetes),  when
circulating levels of β-HB may increase to as much as roughly
20 mM [18]. Equally interesting is the postulated role for
GPR109A in the inflammatory response in certain cell types
[10,19,20]. Increasing evidence points to the involvement of
inflammatory processes in the pathogenesis of several retinal
diseases,  including  diabetic  retinopathy  and  macular
degeneration [19,20]. Thus, determining whether GPR109A
is  expressed  in  retinal  cells  and  understanding  how  the
receptor is regulated in retina would be of immense clinical
relevance, particularly in diabetic conditions when levels of
β-HB are substantially elevated.
METHODS
Reagents:  Reagents  used  in  cell  culture,  retinal  pigment
epithelium (RPE) cell isolation, and RNA extraction, Hoechst
33342,  Image-iT  FX  signal  enhancer,  and  secondary
antibodies were from Invitrogen (Carlsbad, CA). GeneAmp
RT–PCR kit was from Applied Biosystems, Inc. (Foster City,
CA). DIG RNA Labeling Kit was from Roche (Indianapolis,
IN). Taq polymerase kit was from either TaKaRa (Tokyo,
Japan) or Biogenex (San Ramon, CA). cAMP assay kit was
from  Assay  Designs,  Inc.  (Ann  Arbor,  MI).  Primary
antibodies  were  obtained  from  the  following  sources:
peroxidase-conjugated  monoclonal  anti-digoxigenin
antibody (Jackson ImmunoResearch, West Grove, PA); anti-
mouse tyramide signal amplification (TSA)-Cy3 conjugate
(Perkin  Elmer,  Wellesley,  MA);  mouse  monoclonal  anti-
cellular retinaldehyde binding protein (CRALBP), and mouse
monoclonal anti-RPE65 antibody (AbCam, Cambridge, MA);
chicken  polyclonal  anti-monocarboxylate  transporter  1
(MCT1;  Chemicon  International,  Temecula,  CA);
Vectashield Hardset Mounting Media (Vector Laboratories,
Burlingame, CA); [3H]nicotinate (specific radioactivity, 30
Ci/mmol; American Radiolabeled Company, Inc., St. Louis,
MO).
Generation of anti-GPR109A antibody: A rabbit polyclonal
antibody  against  GPR109A  was  generated  commercially
(Genscript Corp., Piscataway, NJ). The antibody was raised
against  the  peptide  sequence  RKKTLGEPDNNRSTSV,
which corresponds to residues 311–326 of mouse GPR109A.
The  corresponding  sequence  in  rat  GPR109A  is
RRKTLGEPDNNRSTSV, which differs from the antigenic
peptide in only one amino acid. The corresponding sequence
in  human  GPR109A  is  QRKMTGEPDNNRSTSV,  which
differs from the antigenic peptide in four amino acids. We
investigated the species specificity of the antibody and found
that the antibody recognizes GPR109A in all three species.
Rodents have a single gene coding for GPR109A, whereas
humans have two closely related genes coding for highly
homologous receptors (GPR109A and GPR109B) [2]. Even
though the amino acid sequences of GPR109A and GPR109B
are similar, GPR109B does not function as a niacin or β-
hydroxybutyrate  receptor.  Since  the  region  containing  the
antigenic peptide is identical in GPR109A and GPR109B, the
antibody is expected to recognize not only GPR109A but also
GPR109B in human tissues or cell lines.
Prior  to  use  in  immunohistochemical  studies,  the
specificity  of  the  antibody  was  confirmed  by  analysis  of
antibody staining in a cell line that does not express GPR109A
constitutively. Briefly, rat, mouse, or human GPR109A was
expressed  in  cells  via  lipofectamine-mediated  transient
transfection  (transfection  efficiency  >90%).
Immunofluorescence  experiments  were  then  performed  in
parallel in nontransfected cells and in GPR109A-transfected
cells.  Nontransfected  cells  served  as  a  negative  control.
Normal rabbit pre-immune serum was used as an additional
negative control, as was peptide-blocked antigenic peptide.
For  peptide  blocking  experiments,  the  anti-GPR109A
antibody was neutralized with 1 μg/ml of the antigenic peptide
and  used  as  a  negative  control  for  immunofluorescence
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antibody was used in nontransfected cells, cells incubated
with pre-immune serum, or peptide-blocked antigenic peptide
(data not shown). However, the antibody gave strong positive
signal  in  cells  transfected  with  the  rat,  mouse,  or  human
GPR109A construct.
Animals: The present study used 3-week-old C57BL/6 mice
for the preparation of total RNA from neural retina and RPE/
eyecup,  and  for  the  establishment  of  primary  RPE  cell
cultures. Albino (Balb/c) mice, age 6–9 weeks, were used for
immunofluorescence  and  fluorescent  in  situ  hybridization
analyses.  All  animals  were  purchased  from  Harlan
(Indianapolis,  IN).  Mice  were  maintained  in  clear  plastic
cages and subjected to standard light cycles (12 h light/12 h
dark). Mice were fed Harlan’s Teklad rodent diet #8604 (min.
crude protein, 24.0%; min. crude fat, 4.0%; max. crude fiber,
4.5%) and water was available ad libitum. Care and use of the
mice adhered to the principles set forth in the Public Health
Service  Policy  on  Humane  Care  and  Use  of  Laboratory
Animals.
Cell  lines:  A  human  retinal  pigment  epithelial  cell  line
(ARPE-19), rat ganglion cell line (RGC-5), and rat Müller cell
line (rMC-1) were cultured in Dulbecco’s modified Eagle
medium (DMEM)/F12 medium and maintained at 37 °C in a
humidified  chamber  of  5%  CO2.  All  culture  media  were
supplemented  with  10%  fetal  bovine  serum,  100  U/ml
penicillin, and 100 μg/ml streptomycin. The culture medium
was  replaced  with  fresh  medium  every  other  day.  Upon
confluency, cultures were passaged by dissociation in 0.05%
(w/v)  trypsin  in  phosphate-buffered  saline  (PBS;  0.01  M
phosphate buffer, 0.0027 M KCl, 0.137 M NaCl, pH 7.4). For
immunocytochemistry,  ARPE-19,  RGC-5,  or  rMC-1  cells
were cultured on glass coverslips for 1–2 days; ARPE-19 cells
were not polarized.
Establishment of primary RPE cell cultures from mouse eyes:
C57Bl/6 mice were used for preparation of primary RPE cell
cultures according to our previously published method [21].
Briefly, enucleated mouse eyes were rinsed in 5% povidone-
iodine  solution,  followed  by  rinsing  with  sterile  Hank’s
Balanced Salt Solution (HBSS). Eyes were then placed in cold
RPE cell culture medium (DMEM:F12), supplemented with
25% fetal bovine serum, 0.1 mg/ml gentamicin, 100 U/ml
penicillin,  and  100  µg/ml  streptomycin.  To  aid  in  the
degradation of extracellular matrix components and enhance
the dissociation of RPE from neural retina and choroid, eyes
were  then  incubated  in  HBSS,  containing  19.5  U/ml
collagenase and 38 U/ml testicular hyaluronidase for 40 min
at 37 °C, followed by incubation in HBSS containing 0.1%
trypsin (pH 8) for 50 min at 37 °C. Eyes were then dissected
to separate RPE from neural retina. Isolated RPE cells were
collected in a 15 ml centrifuge tube and centrifuged at at
1,228  ×  g  for  10  min  (Thermo  Medilite  Centrifuge,
ThermoScientific, Waltham, MA), followed by resuspension
in RPE cell media. RPE cells were then cultured at 37 °C. The
purity  of  RPE  cells  was  evaluated  by  the  expression  of
CRALBP  (a  marker  for  RPE  cells  and  Müller  cells)  and
RPE-65 (a marker for RPE cells) using specific antibodies.
RT–PCR:  Neural  retina  and  RPE/eyecup  were  prepared
according to our previously published method [22] and used
for preparation of total RNA. Briefly, the eye was proptosed
and the cornea slit which immediately released the lens (and
vitreous).  The  retina  was  then  dissected  away  from  the
remaining  RPE-choroid-eyecup  complex.  Tissue  from  six
eyes  were  pooled  for  each  analysis  and  total  RNA  was
prepared.  Total  RNA  was  also  prepared  from  three
transformed retinal cell lines: rMC-1, RGC-5, and ARPE-19.
Primary RPE cells isolated from mouse eyes (mRPE) were
also used for RNA isolation. RT–PCR was performed using
primer pairs specific for mouse, rat, or human GPR109A
(Table  1).  18S  rRNA  or  hypoxanthine  guanine
phosphoribosyltransferase (HPRT) was used as an internal
control for the PCR reaction. The products were subcloned
into  the  pGEM-T  vector  and  sequenced  to  confirm  their
molecular identity.
Fluorescent  in  situ  hybridization:  To  localize  the  mRNA
transcript  encoding  GPR109A  in  intact  mouse  retina,  we
prepared  retinal  cryosections  by  following  our  previously
published method and used these sections for fluorescent in
situ hybridization (FISH) analysis [21,22]. The methods of
Mullis and Faloona [23] and Stoflet et al. [24] were employed
to generate digoxigenin (DIG)-labeled riboprobes, using the
aforedescribed PCR primers for RT–PCR analysis. Briefly,
the 23 bp T7 promoter sequence (5′-TAA TAC GAC TCA
CTA TAG GGA G-3′) was appended to the 5′ end of the
antisense primer such that the promoter was incorporated into
the PCR product. Subsequent amplification of the target DNA
(cDNA  prepared  using  RNA  from  mouse  RPE/eyecup)
yielded  a  PCR  product  that  contained  the  T7  promoter
sequence upstream of the mouse GPR109A sequence. To
produce a template for transcription of the sense (control)
strand of the amplified region, we designed an additional
primer set with the T7 promoter sequence added to the sense-
strand GPR109A primer. These templates were then used for
the synthesis of riboprobes (antisense and sense) with T7 RNA
polymerase. A DIG tag for antibody labeling was added to
sense and antisense probes using a DIG RNA labeling kit
(Roche). Mouse eyes were frozen immediately in Tissue-Tek
Optimal  Cutting  Temperature  compound  (OCT;  Sakura
Finetek, Torrance, CA), and sections were made at 10-µm
thickness and fixed in 4% paraformaldehyde for 30 min at
room temperature. Sections were rinsed in ice-cold PBS and
treated with 0.1% diethylpyrocarbonate prepared in PBS to
facilitate  penetration  of  the  labeled  probe.  Sections  were
permeabilized further with 1 mg/ml proteinase K in PBS for
4 min. The proteinase K activity was stopped by rinsing the
slides in 2 mg/ml glycine in PBS. Sections were washed in
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prehybridized for 2 h at 58 °C in 50% formamide, 5% SSC,
and 50 µg/ml salmon sperm DNA (pH 7.4). Sections were
hybridized  with  1  µg/ml  DIG-labeled  antisense  or  sense
probes and incubated overnight at 58 °C. The sections were
washed under high stringency conditions, first in 2% SSC for
1 h at 65 °C, and then in 0.1% SSC for 1 h at 65 °C, and
transferred to PBS. Immunologic detection of the probe was
performed by blocking sections with PBS-BB (PBS + 1%
BSA,  0.2% powdered skim milk, and 0.3% Triton X-100) for
30  min  at  room  temperature.  DIG-labeled  probes  were
detected by incubating the sections with 1:1000 peroxidase-
conjugated mouse monoclonal anti-digoxigenin antibody for
1 h at room temperature. Sections were then washed in PBS,
followed  by  incubation  with  1:500  anti-mouse  TSA-Cy3
conjugate  30  min  at  room  temperature.  Next,  1:10,000
Hoechst 33342 was used to counterstain the cell nuclei, and
coverslips were mounted using Vectashield Hardset mounting
medium. Sections were examined using a Zeiss Axioplan 2
fluorescent  microscope  equipped  with  an  ApoTome,
AxioVision 4.5 software, and an HRM camera (Carl Zeiss,
Oberkochen, Germany).
Fluorescence immunohistochemistry: To localize GPR109A
protein in intact retina with respect to known markers of RPE
apical  and  basolateral  membranes,  we  employed
immunofluorescent  methods.  Cryosections  of  mouse  eyes
were fixed in 4% paraformaldehyde for 10 min, washed with
PBS, and blocked with 1X Power Block for 10 min at room
temperature. Sections were then incubated overnight at 4 °C
with  1:250  rabbit  polyclonal  anti-GPR109A  antiserum.
Double-labeling studies were performed with 1:1,000 chicken
polyclonal anti-MCT1 as a positive marker for RPE apical
membrane [25,26]. Negative control sections were treated
identically  except  that  primary  GPR109A  antiserum,
neutralized  by  incubation  with  excess  antigenic  peptide
(single-labeling  experiments)  or  PBS  (double-labeling
experiments), was substituted in place of primary antibodies
for overnight incubation. Sections were rinsed with PBS and
incubated for 45 min at room temperature with secondary
antibodies. For detection of GPR109A labeling, sections were
incubated  with  1:1,000  goat  anti-rabbit  Alexa  Fluor  568.
Sections  double-labeled  with  GPR109A  and  MCT1
antibodies were incubated with 1:500 goat anti-rabbit Alexa
Fluor 488 and 1:1,000 goat anti-chicken Alexa Fluor 568,
respectively.
Immunofluorescent  methods  were  used  to  localize
GPR109A protein in cultured ARPE-19, rMC-1, RGC-5, and
primary mouse RPE cells, grown on glass coverslips. Cells
were  air-dried  to  facilitate  better  adhesion  during  the
experiment, and fixed with 4% paraformaldehyde for 5 min
at room temperature. Cells were then washed with PBS and
blocked with Image-iT signal enhancer for 30 min. Incubation
of cells with 1:100 anti-GPR109A-specific primary antibody
was performed overnight at 4 °C. Cells were again washed in
PBS and incubated with 1:1,000 goat anti-rabbit Alexa Fluor
568  for  45  min  at  room  temperature.  Nuclei  were
counterstained with 1:10,000 Hoechst 33342 and coverslips
inverted  and  mounted  on  glass  slides  using  Vectashield
Hardset mounting medium.
cAMP  measurement:  To  determine  whether  GPR109A
expressed on RPE cells was functional, we analyzed the effect
of  the  GPR109A  ligands  nicotinic  acid  and  β-HB  on
intracellular  cAMP  levels  in  ARPE-19  cells.  Briefly,
ARPE-19 cells were seeded at a density of 0.1×106 cells/well
in a 24 well plate. On the third day after seeding, culture
medium  was  removed  and  replaced  with  culture  medium
containing 10 μM forskolin in the presence or absence of
1  mM  nicotinic  acid  or  β-HB  for  1  h.  Measurement  of
intracellular  levels  of  cAMP  was  performed  using  a
commercially available kit and following the manufacturer’s
TABLE 1. SEQUENCES OF RT–PCR PRIMERS.
Gene name Primer sequence Expected product size (bp)
Human GPR109A (HM74A) F: GGACAACTATGTGAGGCGTTGG 650
R: GGGCTGGAGAAGTAGTACACC
Human GPR109B (HM74) F: CGTGATGGACTACTATGTGCG 280
R: ATTTGCAGGGCCATTCTGGAT
Mouse GPR109A (mPUMA-G) F: GTTACAACTTCAGGTGGCACGAT 443
R: CTCCACACTAGTGCTTCGGTTATT
Rat GPR109A (rPUMA-G) F: ACTTTCTGGTGATAAACGGCAAGA 455
R: GACTGTCAGGCCGATGGTG
HPRT1 F: GCGTCGTGATTAGCGATGATGAAC 150
R: CCTCCCATCTCCTTCATGACATCT
18S Universal Standard purchased from Applied
Biosystems/Ambion (Austin, TX) Cat #: AM1716
315
Total RNA was prepared from intact retinal tissues or transformed cell lines and used for analysis of GPR109A expression by
RT–PCR. The specific primer sequences as well as the expected product size for all of the primers used in this study are provided
in this table. All PCR reactions were performed for 35 cycles at an annealing temperature of 58 °C.
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independent  cell  cultures,  and  cAMP  measurements  were
made in triplicate in each experiment. Data are presented as
means±SEM from the three separate experiments.
RESULTS
GPR109A mRNA expression in mouse retina: To determine
whether mRNA transcripts encoding GPR109A were present
in mouse retina, we used RNA isolated from RPE/eyecup and
neural retina for RT–PCR (Figure 1A). PCR was performed
using a primer pair specific for mouse GPR109A (Table 1).
18S rRNA was used as an internal control. GPR109A mRNA
expression was detected in RPE/eyecup, but not in neural
retina. As expected, the actual size of the PCR product was
443 bp. The molecular identity of the product from RPE/
eyecup was confirmed by sequencing. The expression pattern
of GPR109A mRNA in intact retina was then analyzed by
FISH  using  DIG-labeled  antisense  riboprobe  specific  for
mouse  GPR109A  (Figure  1B).  Hybridization  of  retinal
cryosections with GPR109A antisense probe gave a positive
fluorescence (red) signal detectable only in the RPE cell layer
(Figure 1B). The fluorescent signal is specific as evident from
the lack of positive signal in sections hybridized with sense
riboprobe (negative control).
Localization of GPR109A protein in mouse retina: RT–PCR
and FISH analyses demonstrated the presence of GPR109A
mRNA in mouse retina, with expression restricted exclusively
to the RPE. To determine whether GPR109A protein itself
could  be  detected  in  mouse  retina,  we  performed
immunofluorescence analysis using an antibody specific for
GPR109A  (Figure  2  and  Figure  3).  Incubation  of  retinal
cryosections with the antibody gave a positive fluorescence
(red)  signal  only  in  the  RPE  cell  layer  (Figure  2B).  A
corresponding  hematoxylin-  and  eosin-stained  retinal
cryosection is shown in Figure 2A for comparison. Retinal
cryosections  incubated  with  primary  GPR109A  antibody
neutralized  by  incubation  with  excess  antigenic  peptide
showed no positive signal (Figure 2C). Observation of the
RPE  cell  layer  at  higher  magnification  (Figure  2B,  inset)
indicated that positive labeling of GPR109A protein appeared
to be associated specifically with the basolateral membrane of
Figure 1. GPR109A mRNA expression in mouse retina. A: Total RNA collected from mouse neural retina and retinal pigment epithelium
(RPE)/eyecup was used for RT–PCR analysis of GPR109A mRNA expression. GPR109A expression was detected in RPE/eyecup but not in
neural retina. 18S rRNA was used as an internal control. B: Localization of GPR109A mRNA transcripts was evaluated by fluorescent in situ
hybridization (FISH). Hybridization of mouse retinal cryosections with GPR109A-specific antisense probe detected positive (red) labeling
indicative of GPR109A expression in the RPE. No positive signal was detected in sections hybridized with sense (negative control) probe.
Abbreviations: retinal ganglion cell layer (rgc); inner nuclear layer (inl); outer nuclear layer (onl). Magnification of all images in panel B is
200X.
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366this polarized cell. Differential distribution of GPR109A to
the basolateral membrane of RPE, a location conducive to
interaction of the receptor with ligands present in the choroidal
circulation, may have important implications in terms of the
functional role of this receptor in retina. Therefore, to confirm
the  polarized  localization  of  GPR109A  to  the  basolateral
membrane of RPE, we performed additional experiments.
Retinal cryosections were stained with GPR109A antibody
along  with  antibody  against  MCT1  [25,26].
Immunofluorescence analysis of these sections using a Zeiss
Axioplan fluorescent microscope, equipped with an apotome,
revealed the presence of strong positive signals (green) for
GPR109A in the basolateral membrane of RPE (Figure 3).
Positive signals for MCT1 (red) were associated with the
apical membrane of this cellular layer as expected. Merging
of positive signals for GPR109A and MCT1 did not result in
any significant overlap, suggesting that these two proteins do
not  colocalize,  and  that  GPR109A  is  localized  to  the
basolateral membrane of the RPE.
Analysis of GPR109A expression in cultured retinal cells:
Immunofluorescence analysis of cryosections of intact mouse
retina  demonstrated  localization  of  GPR109A  protein
exclusively in RPE, specifically in the basolateral membrane.
To confirm the cell type-specific expression of GPR109A
protein in the retina, we used RT–PCR to detect GPR109A
mRNA in three transformed retinal cell lines: rMC-1, RGC-5,
and ARPE-19 (Figure 4). No product was detectable with
RNA prepared from rMC-1 and RGC-5 cells (Figure 4A),
confirming  the  data  from  the  previously  described
experiments that Müller cells and retinal ganglion cells do not
express the receptor. However, RT–PCR with RNA from
ARPE-19 cells amplified a product of the expected size (650
bp) for GPR109A. Since ARPE-19 is a human cell line, we
also evaluated the expression of GPR109B, the second gene
that codes for a highly homologous receptor in humans. These
studies  showed  that  ARPE-19  cells  express  not  only
GPR109A but also GPR109B (actual product size 280 bp).
The molecular identity of the PCR products obtained from
ARPE-19 cells was confirmed by sequencing.
These results showing RPE-cell-specific expression of
GPR109A  mRNA  were  corroborated  with  data  from
immunofluorescence analysis of the receptor protein (Figure
5).  ARPE-19  cells  incubated  with  GPR109A-specific
antibody were highly positive as indicated by the strong red
fluorescent  signal  (Figure  5A).  Hoechst  33342
counterstaining  of  the  cell  nuclei  is  shown  in  blue.
Immunofluorescence analysis of ARPE-19 cells incubated
with peptide-blocked primary GPR109A antibody (negative
Figure 2. Localization of GPR109A protein in intact retina. A: A hematoxylin and eosin-stained retinal cryosections is provided for comparison
to panel B of the figure. B: Incubation of mouse retinal cryosections with anti- GPR109A antibody revealed positive (red) labeling for
GPR109A protein exclusively in retinal pigment epithelium (RPE). Higher magnification of cryosections reveals that the GPR109A protein
is associated specifically with RPE basolateral membrane (panel B, inset). Hoechst 33342 nuclear stain is shown in blue. In the inset, Nu
means nucleus. C: No labeling was detected in retinal cryosections incubated with primary GPR109A antibody neutralized by incubation with
excess antigenic peptide.
Figure 3. Double-labeling immunofluorescence techniques were employed to determine whether GPR109A protein is expressed apically or
basolaterally in RPE. Chicken polyclonal anti-monocarboxylate transporter 1 (MCT1) was used as a positive marker for RPE apical membrane.
Sections were then viewed and optically sectioned using a Zeiss Axioplan fluorescent microscope equipped with an apotome. Merging of
positive signals for MCT1 (red) and GPR109A protein (green) did not display any significant overlap. Hoechst 33342 nuclear stain is shown
in blue.
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367control) revealed no positive signals (Figure 5B). It has to be
noted  here  that  the  antibody  used  will  not  differentiate
between GPR109A and GPR109B in ARPE-19 cells. There
were no detectable positive signals for GPR109A protein in
rMC-1 (Figure 5C) or RGC-5 (Figure 5D) cells. Since rodents
have  a  single  gene  coding  for  GPR109A,  absence  of
immunopositive signals in rMC-1 and RGC-5 cells show that
the receptor is not expressed in these cells.
Analysis of GPR109A expression in mouse primary RPE cells:
RT–PCR  and  immunofluorescence  studies  of  GPR109A
expression in transformed retinal cell lines provided further
evidence for the expression of the receptor exclusively in
RPE. However, interpretation of the data from ARPE-19 cells
is subject to limitations. First, these cells are transformed and,
therefore, there is no guarantee that the results from this cell
line are extrapolatable to normal RPE cells. Second, ARPE-19
cells are of human origin and thus are expected to express both
GPR109A and GPR109B. This was evident from the RT–PCR
data. Immunofluorescence studies showing positive signals
with GPR109A antibody in ARPE-19 cells are difficult to
Figure  4.  RT–PCR  analysis  of
GPR109A  expression  in  transformed
retinal cell lines. A: RT–PCR of RNA
samples  collected  from  rat  Müller
(rMC-1) and rat ganglion (RGC-5) cells
using  PCR  primers  specific  for  rat
GPR109A did not detect the presence of
mRNA transcripts encoding GPR109A.
18S  rRNA  was  used  as  an  internal
control. B: RT–PCR of RNA samples
collected  from  ARPE-19  cells,  using
primer  pairs  specific  for  human
GPR109A and GPR109B respectively,
detected  the  presence  of  mRNA
transcripts for both isoforms.
Figure 5. Immunofluorescence analysis
of  GPR109A  protein  in  ARPE-19,
rMC-1, and RGC-5 cells. A: ARPE-19
cells  incubated  with  anti-GPR109A
antibody, which detects both GPR109A
and GPR109B, were highly positive. B:
Cells incubated with primary GPR109A
antibody neutralized by incubation with
excess antigenic peptide did not display
any  positive  signal.  Likewise,  no
positive  signal  was  detected  in  rat
Müller  (rMC-1;  C)  and  retinal
ganglion-5 (RGC-5; D) cells incubated
with anti- GPR109A antibody.
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368interpret  because  the  antibody  would  not  differentiate
between GPR109A protein and GPR109B protein. In this
regard, rodents offer a fortuitous model system in which to
study  GPR109A  expression/function,  as  they  only  have  a
single gene coding for the receptor. Therefore, we analyzed
GPR109A  expression  in  primary  cultures  of  RPE  cells
isolated  from  mouse  eyes  (mRPE).  Prior  to  analyzing
GPR109A expression in these cells, we evaluated the purity
of the cells by morphology and by analyzing the expression
of  various  RPE-specific  cell  markers  (Figure  6).  Phase-
contrast microscopic analysis of the cell preparations after 6
days in culture indicated that the cells had large spherical
nuclei and contained numerous dark deposits, suggestive of
the presence of pigment granules (Figure 6A). Analysis of the
cells at higher magnification after several days in culture also
indicated that in addition to displaying robust pigmentation,
cultures  of  these  cells  also  begin  to  exhibit  the  classic
cobblestone morphology characteristic of RPE cells in culture
(Figure  6B).  Using  immunofluorescence  methods,  we
analyzed  the  expression  of  CRALBP,  a  protein  that  is
considered to be a marker for RPE cells (Figure 6C). The cells
were highly positive for CRALBP. However, as retinal Müller
cells are also known to express CRALBP, the RPE cultures
were analyzed also for expression of RPE-65, a RPE-specific
marker  (Figure  6D).  Hoechst  33342  dye  was  used  to
counterstain all cell nuclei. Greater than 95% of cells were
positive for RPE-65 protein expression. Immunofluorescence
for the neuronal marker MAP2 was not positive (data not
shown). Taken together, these data suggest that the method
used to isolate these cells yielded a highly pure population of
RPE cells.
To determine whether mRPE cells express GPR109A,
total RNA was collected from mRPE cells and used for RT–
PCR analysis (Figure 6E). Indeed, mRPE cells were found to
express GPR109A as evidenced by amplification of a 443 bp
product. HPRT was used as an internal control in the PCR
reaction.  The  molecular  identity  of  the  PCR  product  was
confirmed by sequencing. Immunofluorescence techniques
were then used to analyze GPR109A protein expression in
these cells. Cells incubated with primary GPR109A antibody
Figure 6. Analysis of GPR109A mRNA
and protein expression in primary RPE
cells isolated from mouse retina. A: This
phase-contrast image is representative
of the morphology of mouse primary
retinal  pigment  epithelium  (mRPE)
after 6 days in culture. B: In this panel,
the morphology of mRPE cells is shown
at higher magnification. C: mRPE cells
incubated  with  antibody  against
CRALBP were positive for this RPE/
Müller  cell  marker.  D:  mRPE  cells
incubated  with  antibody  against  the
RPE-specific cellular marker, RPE-65,
were  highly  positive.  E:  RT–PCR
analysis of RNA collected from mRPE
cells detected robust GPR109A mRNA
expression. F: Incubation of mRPE cells
with  anti-GPR109A  antibody  yielded
positive  signals.  G:  No  signal  was
detected in mRPE cells incubated with
primary GPR109A antibody neutralized
by  incubation  with  excess  antigenic
peptide.
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369were  highly  positive  (Figure  6F).  No  positive  signal  was
detected in mRPE cells incubated with pre-immune rabbit
serum in place of primary antibody (Figure 6G).
Functional analysis of HM74A expression in ARPE-19 cells:
Analysis  of  GPR109A  mRNA  and  protein  revealed
expression of the receptor in RPE cells. To determine whether
GPR109A receptors expressed in these cells were functional,
we assessed the ability of ligands for GPR109A to decrease
intracellular cAMP levels as demonstrated in other cell types
[5,27]. Treatment of mRPE cells with forskolin increased the
cellular levels of cAMP (Figure 7). Treatment of cells with
forskolin in the presence of the GPR109A ligands, nicotinic
acid  or  β-HB,  decreased  cAMP  levels,  suggesting  that
GPR109A receptors expressed in RPE are functional.
DISCUSSION
To date, GPR109A expression is thought to be restricted to
adipocytes and immune cells. The antilipolytic activity of
niacin  is  explainable  by  the  presence  of  the  receptor  on
adipocytes; the biologic role of the receptor on immune cells
remains to be determined. Recently, β-HB was found to be the
physiologic ligand for the receptor. Patients with diabetes
often  have  marked  elevated  levels  of  this  metabolite  in
circulation. These factors combined with our ongoing interest
in the retina (particularly diabetic retinopathy) prompted us to
ask whether GPR109A is expressed in retina. Prior to the
present study, expression of this receptor in retina has not been
reported in the literature.
Analysis of GPR109A expression in intact retina by RT–
PCR  and  FISH  demonstrated  the  presence  of  GPR109A
mRNA  exclusively  in  RPE.  These  expression  data  were
Figure 7. Functional analysis of GPR109A expression in ARPE-19
cells. ARPE-19 cells were treated in the presence or absence of 10
μM forskolin,1 mM nicotinic acid, or 1 mM β-hydroxybutyrate (β-
HB) for 1 h followed by measurement of intracellular cAMP levels.
Cells incubated in the presence of forskolin alone showed a large
increase in intracellular levels of cAMP. This increase was reduced
by the addition of nicotinic acid or β-HB to the culture medium,
indicating activation of GPR109A. Data are mean±SEM from three
separate experiments.
corroborated by immunofluorescence analysis of GPR109A
protein. As RPE is a polarized cell with distinct apical and
basolateral  membranes,  further  studies  were  devoted  to
determining whether GPR109A expressed in the RPE cell
layer distributes preferentially to one or both of these distinct
membrane compartments. To address this issue, we employed
double-labeling  immunofluorescent  techniques  using  a
marker specific for RPE apical membrane (MCT1). These
studies  demonstrated  unequivocally  that  in  mouse  retina,
GPR109A protein preferentially distributes to the basolateral
membrane in RPE. Data obtained using intact mouse retinal
sections were verified by examining GPR109A mRNA and
protein  expression  in  cultured  RPE  (ARPE-19),  ganglion
(RGC-5), and rMC-1 (Müller) cells. Analysis of GPR109A
mRNA and protein in these cells demonstrated expression of
the receptor only in ARPE-19 cells. Because ARPE-19 cells
are of human origin, the cells expressed not only GPR109A
but also GPR109B. Since GPR109A and GPR109B exhibit
96%  amino  acid  sequence  identity,  it  is  not  possible  to
generate antibodies, which would recognize only GPR109A
in human tissues. Only GPR109A functions as a high-affinity
receptor  for  nicotinate.  In  contrast,  GPR109B  does  not
recognize nicotinate as a ligand. The expression of GPR109A
in RPE was further confirmed with mouse primary RPE cells
as rodents have only a single gene coding for the receptor.
The data presented in the present report demonstrate for
the first time the expression of GPR109A in the retina and,
even more interesting and important, the restriction of its
expression  to  RPE  where  the  receptor  localizes  to  the
basolateral membrane. These findings provide the basis for
future studies designed to determine the functional relevance
of GPR109A expression in retina. The localization of the
receptor to the RPE basolateral membrane places the receptor
in a location conducive to its exposure to substrates in the
choroidal circulation. Binding of ligand to the GPR109A is
associated with decreases in cAMP levels within the cell [5,
8]. In the present study, we found this to be true also in RPE
cells.
In  addition  to  its  roles  in  the  phagocytic  turnover  of
photoreceptor  cells,  and  maintenance  of  the  outer  blood-
retinal barrier, the RPE cell layer is obligatory for the supply
of nutrients to the outer retina, and cAMP is an important
regulator  of  this  process  [15].  Thus,  alterations  of  cAMP
levels in this cellular layer have tremendous implications in
terms of nutrient transport and overall neuronal health and
retinal function. Under normal physiologic conditions, the
GPR109A may have little relevance because of low levels of
β-HB or nicotinate in circulation; however, in conditions such
as uncontrolled type 1 diabetes, when circulating levels of β-
HB are elevated to levels that could have a maximal impact
on receptor activity, the expression of the GPR109A in the
basolateral  membrane  of  RPE  assumes  great  significance
[18].
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370Furthermore,  β-HB  may  not  be  the  only  physiologic
ligand for the receptor. Since this metabolite becomes relevant
only  under  conditions  such  as  prolonged  starvation  and
uncontrolled diabetes, in terms of activation of GPR109A, it
would mean that the receptor does not have any biologic
relevance under normal conditions. This seems unlikely. We
speculate that there may be other ligands, not yet identified,
that may activate the receptor even under conditions when the
levels of β-HB are not elevated. Thus, our discovery that
GPR109A is expressed in retina, particularly in the basolateral
membrane  of  the  RPE,  has  important  physiologic  and
pathologic implications.
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